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Immune modulation has become a central element in many cancer treatments, andT cells
genetically engineered to express chimeric antigen receptors (CAR) may provide a new
approach to cancer immunotherapy. Autologous CAR T cells that have been re-directed
toward tumor-associated antigens (TAA) have shown promising results in phase 1 clinical
trials, with some patients undergoing complete tumor regression. However, this T-cell
therapy must carefully balance effective T-cell activation, to ensure antitumor activity,
with the potential for uncontrolled activation that may produce immunopathology. An
inducible Caspase 9 (iCasp9) “safety switch” offers a solution that allows for the removal of
inappropriately activatedCAR T cells.The induction of iCasp9 depends on the administration
of the small molecule dimerizer drug AP1903 and dimerization results in rapid induction of
apoptosis in transduced cells, preferentially killing activated cells expressing high levels
of transgene. The iCasp9 gene has been incorporated into vectors for use in preclinical
studies and demonstrates effective and reliable suicide gene activity in phase 1 clinical
trials. A third-generation CAR incorporating iCasp9 re-directs T cells toward the GD2 TAA.
GD2 is over-expressed in melanoma and other malignancies of neural crest origin and the
safety and activity of these GD2-iCAR T cells will be investigated in CARPETS and other
actively recruiting phase 1 trials.
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INTRODUCTION TO CAR T-CELL IMMUNOTHERAPY FOR
CANCER
Tumor initiation and progression is sculpted by host immunity
(Shankaran et al., 2001; Fridman et al., 2012). Since recent US FDA
approval of the cancer immunotherapeutic agents, sipuleucel-
T and ipilimumab, for the treatment of prostate cancer and
melanoma, respectively, immunotherapy has joined surgery,
radiotherapy, and chemotherapy as a conventional modality
of treatment for non-hematologic malignancies. Melanoma has
been a particular target of immunotherapy because of its inher-
ent immunogenicity, and early therapeutic approaches such as
interleukin-2 (IL-2) and interferon-alpha2b (IFNα2b) aimed to
stimulate these antitumor immune responses (Mocellin et al.,
2010; Rosenberg, 2014). Recently, monoclonal antibodies (mAb)
that inhibit immune checkpoint signaling molecules such as
CTLA4 (via iplimumab; Hodi et al., 2010; Wolchok et al., 2013),
PD1 or PD-L1, (Hamid et al., 2013; Topalian et al., 2014) have
shown recruitment of cytotoxic T-cell responses. Ex vivo expan-
sion of tumor inﬁltrating lymphocytes (TIL) also aims to boost
the melanoma-speciﬁc immune response and has shown impres-
sive results for selected patients (Rosenberg and Dudley, 2004;
Besser et al., 2013). While most of these therapies rely on a pre-
existing immune response to tumor-associated antigens (TAA),
the adoptive transfer of T cells genetically engineered to express
novel TAA-speciﬁc receptors enables delivery of an antitumor
immunotherapy even in the absence of intrinsic tumor-speciﬁc
immunity (Restifo et al., 2012). The T cells may express either a
transgenic TCR or a chimeric antigen receptor (CAR) and of the
two types of gene modiﬁcation, CAR T cells have shown the most
promise in clinical trials, with over 51 CAR clinical trials currently
registered in the US alone (clinicaltrials.gov).
A ﬁrst-generation CAR typically comprises an antigen-binding
ectodomain of a mAb-derived single chain variable fragment
(scFv) and a signaling endodomain from the CD3ζ molecule.
Following expression, the CAR re-directs the speciﬁcity of the
T cell toward the cognate antigen. Unlike TCR, CAR are inde-
pendent of MHC-restricted antigen presentation, which is a
feature of immune evasion bymany different cancers (Seliger et al.,
1996; Seliger, 2008), and instead can bind directly to TAA, albeit
those located at the cell surface. They can also include multi-
ple intracellular signaling domains from costimulatory molecules.
For example, second-generation CAR may contain CD3ζ and
CD28 signaling domains, while third-generation CAR may con-
tain CD3ζ, CD28 and either OX40 (CD134) or 4-1BB (CD137). T
cells expressing these later generation CAR demonstrate enhanced
activation and effector function (Pule et al., 2005). Autologous
CART cells have shownpromising objective responses in leukemia
and neuroblastoma patients, including some complete and partial
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regressions (Pule et al., 2008; Porter et al., 2011; Grupp et al., 2013).
However, reports of serious adverse events (AEs) in some of these
early trials have raised safety concerns about the technology (see
Table 1).
CAR T-CELL-RELATED SAFETY CONCERNS
The major safety concern for CAR T-cell products is the risk
of on-target but off-tumor effects resulting from T-cell acti-
vation in response to normal tissue expression of the TAA.
Similar off-tumor side-effects have been reported for approved
mAb therapies such as trastuzumab (anti-HER2), which has car-
diotoxicity in some patients due to targeting of HER2-mediated
cardiomyocyte survival pathways, and cetuximab (anti-EGFR),
which produces skin rashes and mucosal irritation related to
EGFR expression on epithelial cells (Perez-Soler et al., 2005; Chien,
2006). In a more recent example, a phase 1 trial of an anti-
EphA2 mAb/cytotoxic drug conjugate was discontinued due to
serious AEs of clinical bleeding and coagulation probably because
of endothelial-cell targeting (Annunziata et al., 2013). Transgenic
TCR T cells likewise feature off-tumor side effects including one
trial which reported MART-1- and gp100-speciﬁc T-cell killing
of normal melanocytes, with the majority of patients experi-
encing widespread erythematous skin rash, transient uveitis or
hearing loss, with most symptoms reversed upon local steroid
treatment (Johnson et al., 2009).While in another trial, transgenic
TCR T cells speciﬁc for the colorectal TAA CEA have resulted
in severe transient colitis (Parkhurst et al., 2011). Thus there are
multiple reports of toxicity by TAA-targeted cell therapies, and
TAA-speciﬁc CART cellsmay also result in the targeting of healthy
tissues.
There is also the theoretical risk of insertional mutagenesis
and oncogenic expansion of transduced cells with retroviral-based
gene therapy. Indeed, such an event has been reported in a gene-
therapy trial for X-linked Severe Combined Immunodeﬁciency
(X-SCID) in which patients received retrovirally transduced
CD34+ bone marrow progenitor cells and four out of nine
patients then developed acute T-leukemia. It is believed that
insertional mutagenesis in the LMO2 proto-oncogene together
with subsequent massive proliferation of the transduced CD34+
progenitor population in immunodeﬁcient hosts contributed to
T-leukemogenesis (Hacein-Bey-Abina et al., 2003, 2010). In con-
trast, similar AEs have not been observed in trials of adoptive
transfer of autologous, polyclonal gene-modiﬁed mature T cells
in immunocompetent hosts (Heslop et al., 2010; Scholler et al.,
2012). However, there is evidence in murine model systems that
mono- or oligo-clonal mature T-cell populations are more sus-
ceptible to insertional mutagenesis (Newrzela et al., 2008, 2011,
2012). Most CAR T cells to date have been manufactured from
polyclonal peripheral blood T cells (Cooper et al., 2006), and even
selected CAR T cells remain polyclonal in respect of their endoge-
nous TCR repertoire (Wang et al., 2012). Nevertheless, insertional
mutagenesis remains a concern and is another consideration in
long-term clinical monitoring, which is a routine part of gene
transfer trials and which helps to establish the safety proﬁle of
CAR T cells.
In addition, CAR T cells may also produce on-target, on-
tumor toxicities more familiar with other cancer therapies. For
example, the tumor lysis syndrome (TLS; Yang et al., 1999; Ji
et al., 2013), cytokine release syndrome (CRS) and the related
macrophage activation syndrome (MAS) that are associated
with some chemotherapies and targeted- or immuno-therapies
(Suntharalingam et al., 2006; Teachey et al., 2013). Importantly
these AEs may occur during the destruction of tumors, and thus
even a successful, on-tumor CAR T-cell effect might result in
toxicity that requires intervention.
CAR T-CELL-RELATED SERIOUS ADVERSE EVENTS
Speciﬁc examples of these toxicities have been observed in sev-
eral CAR T-cell clinical trials (see Table 1). Interestingly, evident
on-target, off-tumor toxicity does not require the incorporation
of additional T-cell costimulatory domains into the CAR con-
struct. In a trial of autologous T-cells expressing a ﬁrst-generation
CAR directed toward carbonic anhydrase IX (CAIX) in patients
with metastatic renal cell carcinoma, NCI-CTC grade 3 or 4 liver
function abnormalities were observed in 4 of 12 patients. This




Grade 3 and 4 transient liver enzyme increases at 1–2 × 109 total cell dose as on-target toxicity
related to CAIX expression on bile duct, preventable by pre-treatment with anti-CAIX monoclonal
antibody.
Lamers et al. (2006, 2013)
CD19 CART cells
(second generation)
Tumor lysis syndrome at 3 × 108/kg total cell dose (1.46 × 105/kg CART cells), resolved by day 26
after infusion.
Severe cytokine-release syndrome, reversible by monoclonal antibody blockade at 1 × 108/kg cell
dose (1.2 × 107/kg CART cells).
Porter et al. (2011),




Respiratory distress and death at 1 × 1010 total cell dose, likely due to CART cell localization to
the lung and “cytokine storm.” Morgan et al. (2010)
CD19 CART cells
(second generation)
Renal failure, “sepsis-syndrome,” elevated cytokine levels and death at 1.2 × 107/kg, possibly due
to a combination of sepsis, cyclophosphamide treatment andT-cell transfer. Brentjens et al. (2010)
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toxicity was subsequently prevented by pre-treatment with an
anti-CAIX mAb (Lamers et al., 2006, 2013).
Two fatal AEs have been reported in phase 1 clinical trials of
an anti-HER2 CAR (Morgan et al., 2010) and of an anti-CD19
CAR (Park andBrentjens, 2010). In the third-generation (CD28.4-
1BB.ζ) anti-HER2 CAR trial, a patient with pulmonary metastases
of colorectal cancer received lymphodepleting chemotherapy fol-
lowed by an intravenous dose of 1010 HER2-CAR T cells. Within
4 h, the patient developed acute respiratory distress and died
5 days later with multi-organ failure. The investigators attributed
her death to a “cytokine storm” hypothesized to result from T-
cell activation on binding of CAR T cells to HER2-expressing
bronchial epithelium. In the trial of a second-generation (CD28.ζ)
anti-CD19 CAR, patients received lymphodepleting chemother-
apy followed by 1.2–3 × 107 CD19-CAR T cells/kg. One patient
developed persistent fevers, respiratory distress and progressive
acute renal failure, and died 44 h post-infusion. Unlike other
patients enrolled in this study, this patient’s serum cytokine levels
were abnormally high after the chemotherapy and before the CAR
T-cell infusion but no higher after the CART-cell infusion, and the
patient’s death was thus attributed to undetected sepsis. However,
the direct attribution of these CAR-related AEs to on-target effects
is confounded by other factors such as high T-cell dose, ﬁrst-pass
through the pulmonary vasculature after intravenous administra-
tion, unintended consequences of conditioning treatments, and
possible underlying infection.
Although second-generation CARs incorporating the CD28
or the 4-1BB costimulatory domains have generally been safe
(Brentjens et al., 2011, 2013; Savoldo et al., 2011), other reports
indicate that serious on-target toxicities including TLS and CRS
have occurred (Brentjens et al., 2010; Kalos et al., 2011; Porter
et al., 2011; Kochenderfer et al., 2012; Grupp et al., 2013). Four
of 8 patients receiving second-generation (CD28.ζ)CD19-speciﬁc
CAR T cells for progressing B-cell malignancies experienced acute
and reversible toxicities, the severity of which correlated with
serum cytokine levels (Kochenderfer et al., 2012). In a trial in
chronic lymphoid leukemia (CLL) patients, one patient developed
TLS after infusion of second-generation (4-1BB.ζ)CD19-CAR T
cells requiring hospitalization on day 22 and treatment with ﬂuid
resuscitation and rasburicase, with symptoms resolving by day 26
(Porter et al., 2011). In a separate trial of CD19-CAR T cells in
acute lymphoblastic leukemia (ALL) patients, two patients expe-
rienced CRS and for one patient this resulted in hospitalization on
day 4 and transfer to intensive care on day 5 after the T-cell infu-
sion (Grupp et al., 2013). The CRS was reversed by anti-cytokine
therapy including tocilizumab (anti-IL-6 receptormAb) and etan-
ercept (decoy TNF receptor). This patient went on to develop
a complete remission, while the other patient had a relapse of
CD19-negative leukemia after 2 months. High levels of IL-10
and IL-6 were also detected in these patients, which suggests a
MAS induced by non-physiologic T-cell activation (Maude et al.,
2014).
As a general statement, early clinical investigation of any
CAR T cell of novel speciﬁcity may result in unpredictable on-
target, off-tumor toxicity. Hence, suicide gene technology can
provide a valuable “safety switch” in these at-risk clinical sce-
narios, allowing for the targeted deletion of inappropriately
activated CAR T cells. Also, although we have focused on CAR
T-cell-related toxicities in this review, it is worth noting that
two patient deaths have been reported for each of two differ-
ent MAGE-A3-speciﬁc transgenic TCR T cells, which resulted
from either neurologic toxicity when brain-expressed MAGE-
A12 was cross-targeted (Morgan et al., 2013) or cardiac toxicity
when heart muscle-expressed Titin was cross-targeted (Linette
et al., 2013). The incidence of these toxicities, and of tumor
burden-related CRS and MAS after CD19-CAR T cell therapy for
B-leukemia (Maus et al., 2014), may be ameliorated by a “safety-
switch” if the suicide gene system chosen is sufﬁciently rapid in
onset.
THE iCasp9 SUICIDE GENE
The herpes simplex virus-thymidine kinase (HSV-TK) suicide
gene system has long been used in cell therapy investigations
as a method for depleting transduced cells in the case of AEs
(Recchia et al., 2006; Ciceri et al., 2009), However, major disad-
vantages attend its use for this purpose. Activation of HSV-TK by
ganciclovir is relatively slow, requiring 3 days to have a complete
effect in vitro (Marin et al., 2012) and although mutant versions
of TK have improved drug sensitivity and killing (Willmon et al.,
2006) the viral TK gene product has intrinsic immunogenicity
that may cause transduced cells to be rejected by the host immune
system in immunocompetent individuals (Riddell et al., 1996;
Berger et al., 2006). Additionally, if ganciclovir is used to treat
CMV infections in immunocompromised recipients of hemopoi-
etic stem transplants then the use of this suicide gene would result
in the unwanted deletion of transduced cells (Bonini et al., 2007;
Sangiolo et al., 2011).
An alternative suicide gene system is CaspaCIDe®, which con-
sists of an inducible caspase 9 (iCasp9) gene together with the
small-molecule, bio-inert, chemical induction of dimerization
(CID) drug, AP1903. The iCasp9 gene contains the intracellular
portion of the human caspase 9 protein, a pro-apoptoticmolecule,
fused to a drug-binding domain derived from human FK506-
binding protein (Clackson et al., 1998; Straathof et al., 2005; see
Figure 1). Intravenous administration of AP1903 produces cross-
linking of the drug-binding domains of this chimeric protein,
which in turn dimerizes caspase9 and activates the downstream
executioner caspase 3 molecule, resulting in cellular apoptosis.
The pharmacokinetics of AP1903 has been studied in a placebo-
controlled, escalating-dose study in volunteers and the drug has
been found to be safe and well tolerated to the highest dose of
1 mg/kg, with plasma levels directly proportional to adminis-
tered dose and rapid reduction to 1% of the maximum plasma
concentration by 10 h (Iuliucci et al., 2001).
In an early preclinical study of this system, it was shown that
expression iCasp9 in, retrovirally transduced Epstein Barr virus-
speciﬁc cytotoxic T lymphocytes (CTLs) in the absence of CID
had no effect on the phenotype or function of the transduced
cells. However, a single 10 nM dose of CID killed 89–93% of
transduced cells by day 7, as measured by GFP expression. These
results were conﬁrmed in vivo in a SCID mouse-human xenograft
model where a single dose killed over 99% of circulating human
GFP+ T cells by day 3. Importantly, killing via iCasp9 has been
found to be extremely rapid with early apoptotic AnnexinV+ cells
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FIGURE 1 | Activation of iCasp9 results in the death of transduced
cells. Inducible caspase 9 (iCasp9) is produced in the transduced cell as a
homodimer with a drug-binding domain. Administration of CID (AP1903 or
AP20187) results in dimerization of caspase 9 leading to an activated form
of the molecule, which then initiates a signaling cascade leading to
apoptosis of the transduced cell.
appearing within 30 min, and a complete effect observed by 24 h
of CID treatment in vitro (Marin et al., 2012).
Other preclinical studies have demonstrated the feasibility of
including retrovirally encoded iCasp9 in cells intended for human
therapy. One study investigated the use of iCasp9-transduced
donor T cells to reduce the risk of donor T-cell-induced graft-
versus-host disease (GvHD) in recipients of a haploidentical stem
cell transplant (Tey et al., 2007). Allodepleted donor T cells were
transduced with a retroviral vector encoding both iCasp9 and a
truncated CD19 molecule as a selectable marker and were shown
to retain effector functions after expansion andmagnetic selection
for the CD19+ population. When these donor T cells were acti-
vatedwith allogeneic PBMC,10nMCIDeffectively killed activated
cells within 24 h in vitrowhile sparing non-activated virus-speciﬁc
T cells.
Another study using a mouse model of T-cell mediated tis-
sue destruction has also shown that the iCasp9/CID system
can be used to rapidly eliminate T cells and block an ongo-
ing autoimmune attack in vivo (de Witte et al., 2008). In this
model, iCasp9-transduced, ovalbumin (OVA)-speciﬁcOT-I trans-
genic T cells destroyed OVA-expressing pancreatic β-cells, and
led to the rapid induction of diabetes and weight-loss that
required euthanasia within 1 week of T-cell administration. How-
ever, CID administration removed 85% of transgenic OT-I T
cells within 2 days, and signiﬁcantly inhibited diabetes devel-
opment so that mice only experienced transient diabetes or
remained normo-glycemic. In this study, homeostatic expansion
of OT-I T cells was also completely halted by CID adminis-
tration, which provides support for the use of the iCasp9/CID
system in adoptive T-cell therapies provided to lymphodepleted
patients.
The ﬁrst preclinical description of CAR T cells includ-
ing an iCasp9 gene was reported by Hoyos et al. (2010)
who developed second-generation CD19-CAR T cells that co-
expressed IL-15 and iCasp9. The authors demonstrated that these
iCasp9/CAR.19/IL-15 T cells had improved effector function and
were effectively eliminated in vivowithin 3days of CIDadministra-
tion, asmeasured by live imaging of luciferase-positive CART cells
(Hoyos et al., 2010). A third-generation, anti-CD20 CAR express-
ing iCasp9 has likewise demonstrated 90% reduction in peripheral
blood CAR T cells in vivo 12 h after CID administration on two
consecutive days (Budde et al., 2013). A study of anti-CD19 CAR
T cells co-expressing a modiﬁed hygromycin resistance/HSV-TK
suicide gene fusion found that transferred T cells did not per-
sist in patients due to anti-transgene immune responses against
the resistance or suicide genes, which highlights the need for
close clinical monitoring of vector persistence and anti-transgene
immunity in clinical trials of T cells expressing iCasp9 (Jensen
et al., 2010).
The iCasp9/CID system has been successfully translated to
a clinical setting. A trial of donor T-cell transfer in stem cell
transplant patients demonstrated that iCasp9 could eliminate
transferred T-cells and endGvHD in patients (Di Stasi et al., 2011).
Five patients who had received CD34+ haploidentical stem cell
transplants for relapsed leukemia were given allodepleted donor
T-cells transduced to express iCasp9 and the truncated CD19
selectable marker. The sorted, CD19+ CD3+ transgenic T-cells
were 90–93% pure, and were able to survive and expand when
transferred to patients. Skin GvHD occurred in four of the ﬁve
patients and liver GVHD occurred in one patient 14–42 days after
T-cell transfer. Treatment of these patients with a single dose of
AP1903 (CID) reduced the numbers of circulating transgenic T
cells by 90% within 30 min of administration, but had no effect
on endogenous T cells and did not cause any AEs.Within 24 h, the
GvHD-associated skin abnormalities were terminated and did not
return, however, non-alloreactive virus-speciﬁc transgenic T cells
were subsequently identiﬁed in patient blood. A long-term follow
up of this clinical study has conﬁrmed that the patients havemain-
tained immune reconstitution, including virus-speciﬁc donor T
cells, without recurrence of GvHD 3.5 years after the initial T-cell
infusion (Zhou et al., 2014). Other trials of iCasp9 gene transfer
in haploidentical donor T cells are also ongoing (NCT01494103,
ACTRN12614000290695).
An important aspect of the iCasp9/CID system is that it enables
the speciﬁc killing of highly activated cells with high levels of trans-
gene expression. As retroviral vectors preferentially integrate near
transcription start sites and genes involved in proliferation (Wu
et al., 2003; Recchia et al., 2006; Cattoglio et al., 2007), it is an inher-
ent feature of the technology that actively dividing cells will have
higher transgene expression andhencehigher levels of iCasp9. Pre-
clinical work suggests that transduced CTLs that are not killed by
CID administration express insufﬁcient iCasp9 to allow functional
activation by CID (Straathof et al., 2005). However, it has been
observed that activation of survivingT cells with down-modulated
transgene expression can rapidly restore CID sensitivity (Tey et al.,
2007). In the GvHD clinical trial, this incomplete depletion of
transduced cells allowed for the re-expansion of the small pop-
ulation of non-alloreactive CD3+CD19+ T cells remaining after
AP1903 treatment. These T cells were rapidly killedwhen activated
and re-exposed to AP1903 ex vivo, indicating that the surviving
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population remained sensitive to AP1903-mediated killing (Di
Stasi et al., 2011). Notwithstanding these results, another in vitro
study has found that immune-selected CTLs remaining after CID
treatment have little or no proliferative potential or functional
transgene activity. The study also found that immune-selected
CTLs rested for 8–9 days after last antigen stimulation can be
depleted signiﬁcantly by CID treatment (Quintarelli et al., 2007).
Hence, the functional signiﬁcance of the iCasp9+T cells surviv-
ing CID treatment remains an open area of investigation. In the
event of AP1903 administration for serious AEs related to either
on-target, on-tumor or on-target, off-tumor effects, the persis-
tence and reactivity of transgene-containing CAR T cells will need
to be determined via studies of patient tissue samples, which may
include attempted ex vivo re-expansion of transgene-containing T
cells.
FUTURE DIRECTIONS: iCasp9-CAR CLINICAL STUDIES
Autologous iCasp9-expressing CAR T cells are being clinically
evaluated in actively recruiting trials. Our imminent phase 1
trial will investigate GD2-speciﬁc and iCasp9-expressing CAR
(GD2-iCAR) T cells in advanced melanoma patients (CARPETS,
ACTRN12613000198729). Autologous patient T cells will be
transduced with a retroviral vector encoding a third-generation
GD2-speciﬁc CD28.OX40.ζ CAR (Pule et al., 2005), which was
developed by the Brenner group in a ﬁrst-generation CAR for-
mat for phase 1 clinical evaluation in neuroblastoma patients
(Pule et al., 2008; Louis et al., 2011), and then modiﬁed further
to encode iCasp9 (Gargett et al., 2014). This third-generation
GD2-iCAR is also currently being investigated in an open phase 1
trial in neuroblastoma patients (GRAIN,NCT01822652), sarcoma
patients (VEGAS, NCT01953900) and other GD2+ solid tumors
(NCT02107963).
GD2 is a disialoganglioside upregulated on the cell sur-
face of tumors of neuroectodermal origin. The GD2-speciﬁc
ch14.18 mAb, which has been included in standard treatment
regimens for high-risk neuroblastoma (Yu et al., 2010), has the
same antigen-binding domain as the 14g2a mAb, which donated
the scFv for the GD2-CAR (Pule et al., 2008; Louis et al., 2011).
Ch14.18, 14g2a and other GD2-speciﬁc mAb can elicit toxicities
such as fever, rash, hypotension, and painful peripheral neuropa-
thy (Saleh et al., 1992; Murray et al., 1994), which probably results
from complement activation (Sorkin et al., 2010). Although such
toxicities are possible in any clinical trial of GD2-CAR T cells,
no signiﬁcant AEs were observed in the clinical study of the
ﬁrst-generation GD2-CAR (Pule et al., 2008; Louis et al., 2011).
Compared to earlier generation receptors, the improved prolifer-
ation, CTL activity and cytokine secretion of the third-generation
GD2-iCAR (Pule et al., 2005) may add to the risk of toxicity either
from enhanced tumor lysis, or on-target, off-tumor effects on
healthy tissues, and thus inclusion of iCasp9 offers the means to
mitigate these risks.
CAR T cells have shown great initial promise in the clinic
but this has been accompanied by some severe and even fatal
side-effects. By signiﬁcantly improving its safety proﬁle, the
iCasp9/AP1903 suicide gene technology can complement CAR
T-cell technology and advance its more widespread adoption in
the clinic.
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